Global Blood Platelets Market Size, Share, Growth Trends & Forecast (2025–2033)

Blood Platelets Market Size & Industry Outlook

The global blood platelets market size reached US$ 4.46 billion in 2024 is expected to reach US$ 7.20 billion by 2033, growing at a CAGR of 5.5% during the forecast period 2025-2033. One of the major drivers of the global blood platelets market is the advancement and adoption of platelet-rich plasma (PRP) and regenerative therapies across various medical fields. PRP therapies, which utilize concentrated platelets to promote tissue repair and healing, are increasingly used in orthopedics, dermatology, dentistry, and cosmetic procedures. The rising popularity of minimally invasive treatments, coupled with growing awareness among healthcare providers and patients about the benefits of PRP, is boosting demand for high-quality platelet products. 

Moreover, innovations in automated platelet collection systems, improved storage solutions, and pathogen-reduction technologies enhance the safety, efficacy, and shelf life of platelet concentrates, further supporting market growth. This combination of expanding therapeutic applications and technological progress is driving significant adoption of platelet products globally.

Key Highlights

• North America dominates the Blood Platelets market with the largest revenue share of 42.5% in 2024.
• The Asia Pacific is the fastest-growing region and is expected to grow at the fastest CAGR of 8.1% over the forecast period.
• Based on Platelet Type, Whole-blood-derived Platelets segment led the market with the largest revenue share of 54.1% in 2024.
• The major market players in the Blood Platelets market includes Aggredyne Inc, Sysmex Corporation, Haemochrom Diagnostics GmbH, Eurobio Scientific, LABiTec Labor BioMedical Technologies GmbH, Arteriocyte Medical Systems, Inc, Biomet, Inc, EmCyte Corporation and among others.

Market Dynamics

Drivers: Rising prevalence of blood disorders driving the blood platelets market growth

The global blood platelets market is experiencing significant growth driven primarily by the increasing prevalence of blood disorders. Conditions like leukemia, lymphoma, aplastic anemia, and immune thrombocytopenia (ITP) result in critically low platelet counts, creating a pressing need for platelet transfusions as a core aspect of patient treatment. For example, patients undergoing chemotherapy for leukemia frequently face treatment-induced thrombocytopenia, which significantly hinders their blood clotting capabilities. In these scenarios, regular platelet transfusions become crucial to avert internal bleeding and enhance recovery outcomes.

For instance, in 2024, the global prevalence of blood disorders continues to rise, significantly impacting the demand for platelet-based therapies and transfusion products. According to recent data, approximately 187,740 new cases of blood cancers, including leukemia, lymphoma, and myeloma, are expected in the United States alone, with nearly 456,000 individuals currently living with or in remission from leukemia. Immune thrombocytopenia (ITP), a major platelet-related disorder, affects around 190,000 diagnosed individuals across the U.S., major European countries, and Japan.

Restraints: Shortage of blood donors are hampering the growth of the blood platelets market

One of the major challenges in the global blood platelets market is the persistent shortage of blood donors. Platelets have a short shelf life of only five to seven days, requiring a continuous and stable supply from voluntary donors. However, declining donation rates, donor eligibility restrictions, and the impact of lifestyle diseases have led to frequent shortages in many regions. Seasonal variations, emergencies, and pandemics further strain blood collection efforts, disrupting hospital inventories and delaying critical treatments. 

This shortage not only affects platelet availability for transfusions in trauma, cancer, and surgical patients but also increases dependence on costly platelet substitutes and imported blood products, posing a significant barrier to meeting global healthcare demands.

For more details on this report – Request for Sample

Segmentation Analysis

The global blood platelets market is segmented based on platelet type, application, end user, and region.

Platelet Type: The whole-blood-derived platelets from platelet type segment to dominate the blood platelets market with a 45.1% share in 2024

The growth of the whole-blood-derived platelets segment is driven by their widespread availability, cost-effectiveness, and critical role in emergency and routine transfusions. These platelets are collected from whole blood donations, making them easier to source and particularly useful in regions with limited access to apheresis technologies. Hospitals and blood centers often rely on whole-blood-derived platelets due to their quick preparation time and suitability for managing trauma, surgical bleeding, and thrombocytopenia. 

Additionally, increasing blood donation drives, expanding transfusion services, and advancements in blood separation and storage technologies are further enhancing the adoption and reliability of whole-blood-derived platelet products globally.

Application: The hemophilia segment is estimated to have a 46.1% of the blood platelets market share in 2024

The hemophilia application segment in the blood platelets market is driven by the growing need for effective management of bleeding disorders and advancements in transfusion and plasma-derived therapies. Patients with hemophilia often require platelet transfusions or platelet-derived products to control excessive bleeding during surgery or injury. Increasing diagnosis rates, rising awareness about blood component therapy, and improved availability of platelet concentrates are supporting market growth. Additionally, ongoing research into recombinant and gene-based platelet substitutes, along with government initiatives to improve treatment accessibility, further strengthen the demand for platelet products in hemophilia management.

Geographical Analysis

North America dominates the global blood platelets market with a 42.5% in 2024

The North American blood platelets market is primarily driven by the high prevalence of blood disorders such as leukemia, thrombocytopenia, and cancer-related complications. Advanced healthcare infrastructure, well-established blood donation networks, and increasing awareness about platelet transfusions support market growth. Furthermore, the adoption of innovative platelet storage and pathogen-reduction technologies ensures a safer and more reliable supply, boosting demand across hospitals and blood centers.

In the USA, rising cases of chronic diseases requiring platelet transfusions, coupled with growing geriatric populations susceptible to hematological disorders, are key growth factors. The country also benefits from significant investments in R&D and regulatory approvals for advanced platelet diagnostics and platelet-rich plasma (PRP) therapies, further encouraging market expansion.

Europe is the second region after North America which is expected to dominate the global blood platelets market with a 34.5% in 2024 

Europe’s market growth is supported by the region’s organized blood banking systems, strong government initiatives for donor recruitment, and increasing awareness about platelet therapies in both clinical and regenerative medicine. The adoption of automated platelet collection and storage systems also enhances supply efficiency and ensures high-quality platelet products.

Germany, as a leading European market, benefits from advanced medical infrastructure, high-quality healthcare standards, and a strong focus on hematology research. Rising cases of hematological cancers and cardiovascular disorders drive demand for platelet transfusions, while supportive reimbursement policies for blood products facilitate market growth.

For instance, in May 2025, PL BioScience GmbH, a German life science company focused on developing and producing Human Platelet Lysate (HPL) for cell culture and expansion, has announced the signing of a Letter of Intent (LOI) with the Korean biotechnology firm DewCell Biotherapeutics. The agreement outlines the supply of artificial platelet-derived raw materials, strengthening collaboration in the field of regenerative medicine and advanced cell therapies.

The Asia Pacific region is the fastest-growing region in the global blood platelets market, with a CAGR of 8.1% in 2024 

The Asia-Pacific market is experiencing growth due to rising incidences of blood-related disorders, increasing surgical procedures, and expanding healthcare access in developing countries. Improved blood donation awareness, coupled with technological advancements in platelet storage and PRP therapy adoption, are key factors driving regional demand.

Japan’s market is fueled by an aging population with higher susceptibility to hematological and cardiovascular disorders. Strong government support for advanced blood therapies, coupled with widespread adoption of platelet-rich plasma (PRP) in regenerative medicine and cosmetic applications, contributes significantly to market growth.

For instance, in June 2025, Japanese researchers have made a major breakthrough by developing a universal, virus-free artificial blood substitute using hemoglobin vesicle technology. This innovation removes the need for blood type matching and offers an extended shelf life of up to two years. Currently in clinical trials, the project aims for real-world medical use by 2030, marking a potential game-changer in global healthcare and emergency medicine.

Competitive Landscape

Top companies in the blood platelets market include Aggredyne Inc, Sysmex Corporation, Haemochrom Diagnostics GmbH, Eurobio Scientific, LABiTec Labor BioMedical Technologies GmbH, Arteriocyte Medical Systems, Inc., Biomet, Inc., EmCyte Corporation and among others.

Aggredyne Inc:- Aggredyne Inc. plays a significant role in the global blood platelets market by providing advanced diagnostic solutions for assessing platelet function and monitoring antiplatelet therapy. Headquartered in Houston, Texas, the company specializes in in-vitro diagnostic systems, with its flagship product, the AggreGuide A-100, offering rapid platelet aggregation analysis using patented light-scattering technology. This system delivers results in under five minutes from a small blood sample, enabling timely clinical decisions in hospitals, physician offices, and reference laboratories.

Market Scope

The global Blood Platelets market report delivers a detailed analysis with 62 key tables, more than 57 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.